In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Aparna A. Kamat and Arthur Hsu to discuss GLP1-RAs and Cancer Risk in Non-diabetic Patients.

Dr. Aparna Kamat is the director of the Division of Gynecologic Oncology for Houston Methodist and is currently the section leader for the Gynecologic Oncology service line. After completing medical training in India, Dr. Kamat completed her residency in OB/GYN at West Virginia University, where she served as chief resident.
She completed her fellowship training in Gynecologic Oncology at the MD Anderson Cancer Center. During her fellowship, she received multiple awards for her research in ovarian cancer and endometrial cancer, including the Virginia K. Pierce award and the Asche Murray fellowship. She also received the prestigious BIRCWH award from the N.I.H. for her research in biomarkers for ovarian cancer. Dr. Kamat currently is the principal investigator for the Gynecologic Oncology Group Clinical Trials Program at Houston Methodist and offers several state-of-the-art clinical trials for patients with gynecologic malignancies. She serves on the board of Ovarcome – a non-profit organization that provides support for women with ovarian cancer and was named Ovarcome Hero of the Year.
Her areas of expertise are robotic and minimally invasive surgical options for women with gynecologic cancers and complex pelvic disease. Her other clinical interests include hereditary risk assessment and treatment of gynecologic malignancies.

Arthur Heng-Cheng Hsu, MD, is a gynecologic oncologist at the National Taiwan University Hospital and focuses on surgery, cancer therapy, and patient recovery. He serves as the Director of Journal Operations for the International Journal of Gynecological Cancer (IJGC). His recent work is published in the Annals of Oncology exploring GLP-1 receptor agonist use and cancer risk in obese, non-diabetic adults.